Mild cognitive impairment: Disease modification/Anti-amyloid or neuroprotective

AZTherapies ( Phase 3 study of inhaled cromolyn sodium combined with ibuprofen to prevent aggregation of beta amyloid fibrils and reduce neuroinflammation. Wechsler Memory Scale ≤8 for those w ≥16 yrs education and ≤4 with less education, CDR=0.5, ages 55-79, positive CSF biomarkers for AD. RPCT with 4 treatment arms (1 arm with both active treatments, 1 with two placebos, etc.). Primary outcome is CDR-SOB at week 72.